S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL

• A. Zelenetz,
• W. Jurczak,
• V. Ribrag,
• K. Linton,
• G. Collins,
• J. Lopéz-Jiménez,
• N. Reddy,
• A. Mengarelli,
• T. Phillips,
• G. Musuraca,
• O. Sheehy,
• J. Li,
• W. Xu,
• M. Azoulay,
• R. Ghalie,
• P. L. Zinzani

Affiliations

A. Zelenetz

1 Memorial Sloan Kettering Cancer Institute, New York City, United States of America

W. Jurczak

2 Maria Sklodowska Curie National Research Institute of Oncology, Krakow, Poland

V. Ribrag

3 Institut Gustave Roussy, Villejuif, France

K. Linton

4 Manchester Cancer Research Centre, Manchester

G. Collins

5 GenesisCare, Oxford, United Kingdom

J. Lopéz-Jiménez

6 Hospital Universitario Ramon y Cajal, Madrid, Spain

N. Reddy

7 Vanderbilt University, Nashville, United States of America

A. Mengarelli

8 Regina Elena National Cancer Institute, Roma, Italy

T. Phillips

9 University of Michigan Health System, Ann Arbor, United States of America

G. Musuraca

10 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I.R.S.T., Meldola, Italy

O. Sheehy

11 Belfast Health and Social Care Trust, Belfast, United Kingdom

J. Li

12 MEI Pharma, Inc., San Diego

W. Xu

12 MEI Pharma, Inc., San Diego

M. Azoulay

13 Kyowa Kirin Co., Princeton, United States of America

R. Ghalie

12 MEI Pharma, Inc., San Diego

P. L. Zinzani

14 University of Bologna, Bologna, Italy